Thuggacins, Macrolide Antibiotics Active Against Mycobacterium tuberculosis: Isolation from Myxobacteria, Structure Elucidation, Conformation Analysis and Biosynthesis.

ChemInform ◽  
2007 ◽  
Vol 38 (46) ◽  
Author(s):  
Heinrich Steinmetz ◽  
Herbert Irschik ◽  
Brigitte Kunze ◽  
Hans Reichenbach ◽  
Gerhard Hoefle ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Structure Elucidation ◽  
Macrolide Antibiotics ◽  
Conformation Analysis

Thuggacins, Macrolide Antibiotics Active againstMycobacterium tuberculosis: Isolation from Myxobacteria, Structure Elucidation, Conformation Analysis and Biosynthesis

2007 ◽  
Vol 13 (20) ◽  
pp. 5822-5832 ◽  
Author(s):  
Heinrich Steinmetz ◽  
Herbert Irschik ◽  
Brigitte Kunze ◽  
Hans Reichenbach ◽  
Gerhard Höfle ◽  
...  
Keyword(s):  
Structure Elucidation ◽  
Macrolide Antibiotics ◽  
Conformation Analysis

scholarly journals Quinolidomicins Al, A2 and B1, novel 60-membered macrolide antibiotics. II. Structure elucidation.

1993 ◽  
Vol 46 (10) ◽  
pp. 1563-1569 ◽  
Author(s):  
YOICHI HAYAKAWA ◽  
KAZUO SHIN-YA ◽  
KAZUO FURIHATA ◽  
HARUO SETO
Keyword(s):  
Structure Elucidation ◽  
Macrolide Antibiotics

ChemInform Abstract: Kanchanamycins, New Polyol Macrolide Antibiotics Produced by Streptomyces olivaceus Tue 4018. Part 2. Structure Elucidation.

ChemInform ◽  
2010 ◽  
Vol 28 (6) ◽  
pp. no-no
Author(s):  
H. STEPHAN ◽  
C. KEMPTER ◽  
J. W. METZGER ◽  
G. JUNG ◽  
O. POTTERAT ◽  
...  
Keyword(s):  
Structure Elucidation ◽  
Macrolide Antibiotics ◽  
Streptomyces Olivaceus

scholarly journals Biosynthesis of the redox cofactor mycofactocin comprises oligoglycosylation by MftF in Mycolicibacterium smegmatis

2019 ◽  
Author(s):  
Luis Peña-Ortiz ◽  
Ana Patrícia Graça ◽  
Huijuan Guo ◽  
Daniel Braga ◽  
Tobias G. Köllner ◽  
...  
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Metabolic Profiling ◽  
Drug Target ◽  
Structure Elucidation ◽  
Potential Drug Target ◽  
Potential Drug ◽  
Alcohol Metabolism ◽  
Future Studies ◽  
Mycobacterial Diseases

AbstractMycofactocin (MFT) is a redox cofactor involved in alcohol metabolism of mycobacteria including Mycobacterium tuberculosis. In recent years, a preliminary biosynthetic model of MFT has been established by in-vitro studies, while the final structure of MFT remained elusive. Here, we report the discovery of MFT by metabolomics and establish a model of its biosynthesis in Mycolicibacterium smegmatis. Structure elucidation revealed that MFT is decorated with up to nine β-1,4-linked glucose residues. Dissection of biosynthetic genes demonstrated that the oligoglycosylation is catalyzed by the glycosyltransferase MftF. Furthermore, we confirm the cofactor function of MFT by activity-based metabolic profiling using the carveol dehydrogenase LimC and show that the MFT pool expands during cultivation on ethanol. Our results close an important gap of knowledge, will guide future studies into the physiological roles of MFT in bacteria and may inspire its utilization as a biomarker or potential drug target to combat mycobacterial diseases.

scholarly journals Kanchanamycins, New Polyol Macrolide Antibiotics Produced by Streptomyces olivaceus Tue 4018. II. Structure Elucidation.

1996 ◽  
Vol 49 (8) ◽  
pp. 765-769 ◽  
Author(s):  
HOLGER STEPHAN ◽  
CHRISTOPH KEMPTER ◽  
JÖRG W. METZGER ◽  
GÜNTHER JUNG ◽  
OLIVIER POTTERAT ◽  
...  
Keyword(s):  
Structure Elucidation ◽  
Macrolide Antibiotics ◽  
Streptomyces Olivaceus

New Macrolide Antibiotics: Usefulness in Infections Caused by Mycobacteria other Than Mycobacterium Tuberculosis

1994 ◽  
Vol 28 (11) ◽  
pp. 1255-1263 ◽  
Author(s):  
Robert P. Rapp ◽  
Scott A. McCraney ◽  
Norman L. Goodman ◽  
David J. Shaddick
Keyword(s):  
Mycobacterium Tuberculosis ◽  
Antimicrobial Agents ◽  
New Drugs ◽  
Vitro Activity ◽  
Great Promise ◽  
Macrolide Antibiotics ◽  
Mycobacterium Fortuitum ◽  
In Vitro Activity ◽  
Mycobacterium Chelonae

OBJECTIVE: To compare the pharmacology, in vitro activity, and clinical use of the new macrolide antibiotics, azithromycin and clarithromycin, in the treatment of infections caused by mycobacteria other than Mycobacterium tuberculosis. DATA IDENTIFICATION: An English-language literature search using MEDLINE (1987–1994), Index Medicus (1987–1994), Program and abstracts of the 31st (1991) and 32nd (1992) Interscience Conference on Antimicrobial Agents and Chemotherapy, and bibliographic reviews of related textbooks, review articles, and professional society publications. STUDY SELECTION: 105 articles were selected. In vitro and in vivo reports on the pharmacokinetics, microbiology, pharmacology, and effectiveness of clarithromycin and azithromycin were assessed to compare their effectiveness and safety. Emphasis was placed on the use of these new drugs in treating infections caused by Mycobacterium avium complex, Mycobacterium chelonae, and Mycobacterium fortuitum infections. RESULTS: A review of the in vitro activity of the new macrolides revealed moderate to very good activity against many strains of mycobacteria other than M. tuberculosis. Early clinical trials show promising results in pulmonary infections, lymphadenitis, cutaneous infections, and disseminated infections. CONCLUSIONS: The new macrolides, azithromycin and clarithromycin, show great promise for treating infections caused by these acid-fast bacteria. Clarithromycin is recommended as a component of combination therapy for the treatment of M. avium complex infections in patients with AIDS. The development of resistance in patients, particularly when these agents are used alone, has been reported.

Sign in / Sign up

Export Citation Format

Share Document